Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus FLUOROMETHOLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus FLUOROMETHOLONE.
BREO ELLIPTA vs FLUOROMETHOLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce phospholipase A2 inhibitory proteins, thereby reducing prostaglandin and leukotriene synthesis. Exhibits anti-inflammatory, antipruritic, and vasoconstrictive effects.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
1-2 drops of 0.1% suspension in conjunctival sac 2-4 times daily; severe cases: every 4 hours initially, then taper. Ointment: 0.5 inch ribbon 1-3 times daily.
None Documented
None Documented
Clinical Note
moderateFluorometholone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Gatifloxacin."
Clinical Note
moderateFluorometholone + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Rosoxacin."
Clinical Note
moderateFluorometholone + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin."
Clinical Note
moderateFluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life: 1.3–2.2 hours; However, the pharmacodynamic half-life (duration of adrenal suppression) is longer (~24–36 hours) due to receptor-mediated effects.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (primarily as metabolites): ~70%; Fecal: ~20%; Unchanged in urine: <5%
Category C
Category A/B
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid
Fluorometholone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Trovafloxacin."